Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

CanTx, Novogen name two key CMOs to manufacture clinical batches of anti-cancer drug Cantrixil

Oncology drug developer, CanTx Inc., and its parent company, Novogen Ltd., today announced that they have named two key contract manufacturing organizations (CMOs) to produce clinical batches of the experimental anti-cancer drug, Cantrixil.

26 Jul 2014

Malvern acquires MicroCal business and Affinity Biosensors' Archimedes product

Malvern Instruments Ltd (Malvern, UK) has today announced that it has completed the acquisition of MicroCal from GE Healthcare Life Sciences and has also purchased the Archimedes particle characterization system from Affinity Biosensors LLC (Santa Barbara, CA).

25 Jul 2014

WIRB-Copernicus Group acquires Alliance Biosciences

WIRB-Copernicus Group, the world's largest provider of regulatory and ethical review services for clinical research, announced today that it has acquired Alliance Biosciences. Formerly a division of Richmond, VA-based Alliance Engineering, Alliance Biosciences was the leading biosafety and biosecurity consulting firm in the United States.

24 Jul 2014

Capsazepine shows dramatic tumor shrinkage without damaging surrounding tissues

Mouse models of human oral cancer treated with an agent called capsazepine showed dramatic tumor shrinkage without damage to surrounding tissues, researchers from the School of Dentistry and School of Medicine at The University of Texas Health Science Center at San Antonio found.

24 Jul 2014

New chromatin immunoprecipitation sequencing kit developed by Porvair Sciences

Porvair Sciences has developed a new ChIP sequencing assay kit extending the benefits of their proprietary Chromatrap® solid state ChIP technology to preparation of purified Chromatin for the generation of sequencing libraries.

From Chromatrap® - Porvair Sciences Ltd 22 Jul 2014

Unnatural DNA bases: an interview with Professor Floyd E. Romesberg, The Scripps Research Institute

The natural DNA bases that form the letters of DNA are usually referred to as G, C, A, and T. Those are only the first letters of the chemical names. They’re often called nucleotides by their scientific name and all of them have in common a phosphate part, a sugar part and a nucleobase part.

21 Jul 2014

Chemoprevention and colon cancer: an interview with Dr. John Letterio, Case Western Reserve University School of Medicine

The basic idea of cancer chemoprevention is to arrest or reverse the progression of premalignant cells towards full malignancy, using physiological mechanisms that do not kill healthy cells.

16 Jul 2014

Research shows promise to speed up drug discovery for deadly diseases

Antibiotic resistance is depleting our arsenal against deadly diseases and infections, such as tuberculosis and Staph infections, but recent research shows promise to speed up the drug discovery process.

16 Jul 2014

Pareto partners with DNA2.0 to develop technology for quick-to-market products

Synthetic biology company Pareto Biotechnologies today announces a technology partnership with global bioengineering leader DNA2.0, enabling Pareto to further develop its technology for quick-to-market products.

14 Jul 2014

MIIR partners with international biosciences to develop potential anti-cancer drugs

The Marshall Institute for Interdisciplinary Research (MIIR) and the Marshall University Joan C. Edwards School of Medicine today announced they will be partnering with an international biosciences company to develop potential anti-cancer drugs.

11 Jul 2014

HD Biosciences and MIIR partner to co-develop potential anti-cancer drugs

HD Biosciences Co., Ltd. (HDB), the Marshall Institute for Interdisciplinary Research (MIIR) and the Marshall University Joan C. Edwards School of Medicine announced the new partnership to co-develop potential anti-cancer drugs.

10 Jul 2014

MEF2 gene: A potential therapeutic target to protect neuronal loss in Alzheimer's, Parkinson's

A new study by researchers at Sanford-Burnham Medical Research Institute (Sanford-Burnham) has identified a chemical "switch" that controls both the generation of new neurons from neural stem cells and the survival of existing nerve cells in the brain.

4 Jul 2014

BioTek launches the new Epoch™ 2 Microplate Spectrophotometer

BioTek proudly unveils the new Epoch™ 2 Microplate Spectrophotometer. Epoch 2 is the first reader to combine a large touchscreen and full onboard data analysis software for simplified and efficient operation and reporting of absorbance-based detection workflows.

2 Jul 2014

Mayo Clinic researchers uncover 31 genes key to clear cell renal cell carcinoma

A genomic analysis of clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer, from 72 patients has uncovered 31 genes that are key to development, growth and spread of the cancer, say researchers from Mayo Clinic in Florida.

2 Jul 2014

INTEGRA introduces Row Dilution Plate Holder accessory for VIAFLO 96 and 384 handheld benchtop pipettes

INTEGRA has introduced a Row Dilution Plate Holder accessory for its VIAFLO 96 and 384 handheld benchtop pipettes.

From INTEGRA Biosciences 30 Jun 2014

Video interview highlights latest research developments in women’s reproductive health using Chromatrap solid state ChIP assay

An informative video interview with Professor Steve Conlan of the College of Medicine at Swansea University (UK) highlights the latest research developments in women’s reproductive health using unique molecular biology tools.

From Chromatrap® - Porvair Sciences Ltd 30 Jun 2014

Newly identified compound may halt progression of Alzheimer's disease

Without a steady supply of blood, neurons can't work. That's why one of the culprits behind Alzheimer's disease is believed to be the persistent blood clots that often form in the brains of Alzheimer's patients, contributing to the condition's hallmark memory loss, confusion and cognitive decline.

28 Jun 2014

Public health issues: Climate change; funding for Alzheimer's research

A medical expert calls for hospitals and health care officials to begin to plan for global warming problems, and The Wall Street Journal looks at new ways to finance research.

27 Jun 2014

G protein-coupled receptors: Natural targets for new drug development

They are the largest family of receptors on the surface of our cells, and they help us maintain basics like blood pressure and heart rate.

26 Jun 2014

Mersana and Merck KGaA develop next-generation antibody-drug conjugates

Mersana Therapeutics, Inc., and the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, which operates as EMD Serono in the United States and Canada, announced today an agreement to collaboratively develop next-generation antibody-drug conjugates (ADCs).

24 Jun 2014